Trujillo, Peru Clinical Trials

A listing of Trujillo, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

cancer chemotherapy
lung carcinoma
durvalumab
Research Site
 (0.8 away) Contact site
  • 102 views
  • 25 Jul, 2021
  • +245 other locations
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Research Site
 (4.8 away) Contact site
  • 84 views
  • 31 Jul, 2021
  • +292 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102)
 (0.9 away) Contact site
  • 175 views
  • 02 Aug, 2021
  • +146 other locations
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

cancer chemotherapy
EGFR
osimertinib
carboplatin
lung carcinoma
Research Site
 (4.8 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +138 other locations
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due …

cancer treatment
egfr t790m
EGFR
tyrosine
osimertinib
Research Site
 (4.8 away) Contact site
  • 811 views
  • 21 Jul, 2021
  • +171 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

EGFR
durvalumab
lung carcinoma
paclitaxel
pemetrexed
Research Site
 (4.8 away) Contact site
  • 251 views
  • 31 Jul, 2021
  • +318 other locations